Two Bottles, Same Herb, Different Drug

Ashwagandha is, by search volume, the most talked-about adaptogen in the world right now — global interest in the herb has risen sharply over the past five years. It's also one of the clearest examples of a problem I wrote about last week: the gap between a plant being screened by tradition and a plant being validated by science.

Here's the short version of that gap, specific to this one herb: two bottles can both say "Ashwagandha" on the label, be sold at similar prices, and do almost nothing alike in your body.

The Root of the Confusion — Literally

Ashwagandha's active compounds are a class of molecules called withanolides. They're concentrated unevenly across the plant — the root and the leaf carry different profiles, and raw, unprocessed powder carries them in far lower concentration than a standardized extract does.

This is why clinical trials on Ashwagandha almost never test "ashwagandha" in the abstract. They test a specific, standardized extract — a defined withanolide percentage, a defined root-to-leaf ratio, manufactured to be consistent batch to batch. The two most commonly studied branded extracts, for instance, differ from each other in exactly this way: different concentration targets, different plant-part ratios, and — accordingly — different trial results for different outcomes like stress markers or sleep quality.

Put a generic root powder in a capsule, and you may be giving someone a small fraction of the active dose that produced the result they read about online.

Why This Isn't a Minor Technicality

It's tempting to treat "standardized extract vs. raw powder" as a fine-print detail. It isn't. It's the difference between a product built to replicate a clinical result and a product built to say a plant name on the front of a package.

This is the same failure pattern from the Screening Problem: tradition correctly identified that this root does something. It never had the tools to specify precisely what, in what concentration, from which part of the plant. That specification work is exactly what standardization is — and exactly what most of the market skips, because unstandardized root powder is dramatically cheaper to source than a tested, concentration-verified extract.

The Actual Question to Ask

Not "does this product contain Ashwagandha" — almost everything does. The real question: does the label name a specific standardized extract, at a specific withanolide concentration, and is that concentration in the range that's actually been studied for the outcome being claimed (stress, sleep, recovery — these aren't interchangeable, and not every extract has been studied for every outcome).

If a label just says "Ashwagandha root powder, 500mg" with no extract name and no withanolide percentage, you have no way to know whether you're holding a validated dose or a rounding error.

Where This Leaves the Category

Ashwagandha isn't overhyped as a compound — the clinical literature on standardized extracts is genuinely one of the stronger evidence bases in the herbal category. What's overhyped is the assumption that any product bearing the name shares that evidence base. It doesn't, unless it's built to.

That's a solvable problem. It just requires treating extract specification as a non-negotiable, not a nice-to-have — which is a smaller ask than it sounds, and a bigger one than most of the market is currently willing to make.